Know Labs receives new patent for its non-invasive diagnostic technology platform, bringing the number of issued and pending patents to nearly 60
SEATTLE, June 22, 2021– (COMMERCIAL THREAD) –Know Labs, Inc. (OTCQB: KNWN), an emerging leader in non-invasive medical diagnostics, today announced that it has obtained an additional patent for its Bio-RFID ™ technology, bringing its significant portfolio of patents to 57 issued and pending patents, a important step for the company.
“We are building a revolutionary platform technology that will revolutionize medical diagnostics, starting with what we believe to be the world’s first non-invasive glucose monitoring device,” said Phil Bosua, CEO of Know Labs and inventor of Bio -RFID. “This patent is essential because without the ability to control the timing of frequency capture, precise non-invasive measurements using radio frequency on the human body are not possible. We have obtained 22 patents to date and 35 more are pending. Our advancements will lead to breakthroughs in diagnosis and potentially disease prevention, so we pursue and implement a disciplined intellectual property strategy to protect our innovative technology and its value. ”
US Patent No. 11,033,208 was published by the United States Patent and Trademark Office and is titled “Fixed Run Time Frequency Scans for an Analyte Sensor.” The patent relates to how the operation of Know Labs’ Bio-RFID sensor technology is controlled. The detection routines conducted by the sensor to non-invasively detect an analyte in the body are conducted substantially identically to each other, which means that the results are obtained under conditions as close to the same as possible. This allows for a more accurate comparison between the results of each detection routine, increasing the precision and accuracy of Know Labs’ Bio-RFID sensor technology to non-invasively measure and identify a variety of analytes, including the glucose.
Know Labs recently announced the positive results of an independent preclinical study validating the company’s Bio-RFID technology. This recently issued patent demonstrates the accuracy and sensitivity of the sensor, which is required to pass FDA clinical trials for the company’s non-invasive blood glucose meter.
Know Labs will continue to align its product development efforts with its intellectual property strategy. The company continues to file new patents on a regular basis and will provide further details on the scope and scope of its intellectual property portfolio as the patents are issued.
About Know Labs, Inc.
Know Labs, Inc. is a public company whose shares trade under the ticker symbol “KNWN”. The Company’s technology uses spectroscopy directing electromagnetic energy through a substance or material to capture a unique molecular signature. The Company calls its technology Bio-RFID ™. Bio-RFID technology can be integrated into a variety of portable, mobile, or benchtop form factors. This patented and patent-pending technology enables efficient performance of analyzes that previously could only be performed by invasive and / or expensive and time-consuming laboratory tests. The first application of our Bio-RFID technology will be in a product marketed as a glucometer. It will provide the user with real-time information on their blood sugar. This product will require approval from the United States Food and Drug Administration prior to its market introduction.
Safe Harbor Declaration
This press release contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and section 27A of the Securities Act of 1933, as amended, and section 21E of the Securities Exchange Act of 1934, as as modified. These statements appear in several places in this release and include all statements that are not statements of historical fact concerning the intention, belief or current expectations of Know Labs, Inc., its directors or officers in this regard. which concerns, inter alia: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy; and (iv) product performance. You can identify these statements using the words “may”, “will”, “could”, “should”, “should”, “plans”, “expects”, “anticipates”, “continue”, “Estimate,” “plan”, “intention”, “probable”, “forecast”, “probable”, “potential” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that these forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the control of Know Labs, Inc., and actual results may differ materially from those projected in the forecast forward-looking statements due to various factors. These risks and uncertainties also include additional risk factors as discussed in documents filed by the Company with the United States Securities and Exchange Commission, including its annual report on Form 10-K for the year ended 30 September 2020, Forms 10-Q and 8 -K, and in other documents that we make from time to time with the Securities and Exchange Commission. These documents are available in the SEC Filings section of the Investor Relations section of our website at www.knowlabs.co. The Company cautions readers not to place undue reliance on these forward-looking statements, which speak only as of the date of their publication. The Company assumes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20210622005332/en/
Contact from Know Labs, Inc .:
Jordyn (Theisen) Hujar
Phone. (206) 629-6414